文献速递免疫规划

注射用人乳头瘤病毒疫苗作为滴眼液给药的有效性和安全性

Effectiveness and safety of injectable human papilloma virus vaccine administered as eyedrops.
PubMed 文献 · Vaccine · 2022-11-17

本研究在小鼠中评估市售人乳头瘤病毒(HPV)疫苗Cervarix经滴眼途径接种的免疫原性和安全性。滴眼接种后小鼠产生显著的抗HPV抗原特异性IgG和IgA抗体反应,24小时内接种部位未见炎症迹象,角膜和视网膜形态及眼压未改变,光感受器细胞功能正常。结果提示Cervarix滴眼疫苗可能是针对HPV相关癌症的有效、安全的黏膜疫苗。

要点

  • Cervarix滴眼接种在小鼠中诱导显著抗HPV抗原特异性IgG和IgA抗体产生。
  • 接种后24小时内接种部位未见炎症细胞因子mRNA水平升高或单核细胞浸润。
  • 接种后小鼠角膜和视网膜形态、眼压及光感受器细胞功能均正常。

核心结论

  • 结果表明Cervarix滴眼疫苗可能是针对HPV相关癌症的有效、安全的黏膜疫苗。

研究设计与样本

  • 本研究为小鼠实验,评估市售HPV疫苗Cervarix经滴眼途径接种的免疫反应和安全性。

主要发现

  • Cervarix滴眼接种后小鼠产生显著抗HPV抗原特异性IgG和IgA抗体。
  • 接种后24小时内接种部位炎症细胞因子mRNA水平和单核细胞浸润未见炎症迹象。
  • 接种后小鼠角膜和视网膜形态及眼压未改变。
  • 接种后小鼠视杆细胞和视锥细胞等光感受器细胞功能正常。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mucosal vaccines have the advantages of ease of administration and the induction of strong mucosal immunity and a systemic immune response. Recently, the eye mucosa has been shown to be an effective and safe alternative vaccination route against influenza, Toxoplasma gondii infection, and hemolytic uremic syndrome in mice. In this study, we showed that the commercially available human papilloma virus (HPV) vaccine, Cervarix, induced significant immune reactions in terms of anti-HPV antigen (Ag)-specific immunoglobulin G (IgG) and IgA antibody production following eyedrop (ED) vaccination in mice. The HPV ED vaccines (EDV) provoked no signs of inflammation within 24 h, as indicated by the inflammatory cytokine mRNA levels and infiltration of mononuclear cells in inoculation sites. Moreover, the morphology of the cornea and retina and intraocular pressure of mice did not change after the HPV EDV. The functions of photoreceptor cells, including rod and cone cells, were normal following the HPV EDV inoculation in mice. These results suggest that Cervarix EDV could be a potent, safe, and effective mucosal vaccine against HPV-associated cancers.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kim J, Kim ED, Shin HS, et al. Effectiveness and safety of injectable human papilloma virus vaccine administered as eyedrops. Vaccine. 2022. PMID: 36402660. doi:10.1016/j.vaccine.2022.09.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。